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Abstract
Significant pharmacokinetic interactions can result between acid-suppressing agents and some protease inhib-
itors (PIs) in the management of HIV infection. In healthy subjects, famotidine, an H2-receptor antagonist,
reduces exposures of atazanavir by 4–28% at doses of 20–40 mg twice daily. This study evaluated the effect of
famotidine 20–40 mg twice daily on the pharmacokinetics of atazanavir/ritonavir 300/100 mg once daily with
and without tenofovir disoproxil fumarate (TDF) 300 mg in HIV-infected patients (n = 40; 87.5% male; mean age
42, range 26–63 years; 55% white). Coadministration of famotidine 40 mg and atazanavir/ritonavir to HIV-
infected patients reduced exposures of atazanavir by approximately 20%. This is comparable to reductions seen
in HIV-uninfected subjects. Coadministration of famotidine 20 mg had less impact on atazanavir exposures, with
no reduction of atazanavir geometric mean plasma concentration at 24 h postdose (Cmin). In the presence of TDF,
administration of famotidine 20–40 mg twice daily 2 h after and 10 h before atazanavir/ritonavir reduced
exposures of atazanavir by 19–25%. However, all individual atazanavir Cmin values remained at least five-fold
above the population mean protein-binding adjusted 90% maximum effect (EC90) against wild-type HIV (14 ng/
mL). No viral load rebound was observed at end of study. The results confirmed that coadministration of
an H2-receptor antagonist with atazanavir/ritonavir in HIV-infected patients resulted in similar magnitude of
reductions in atazanavir exposures as in healthy subjects. This supports the current dose recommendations for
coadministration of an H2-receptor antagonist with atazanavir/ritonavir.
Introduction
Atazanavir is a potent once-daily protease inhibitor (PI)for the treatment of HIV type I infection, with proven
efficacy in both treatment-experienced and treatment-naı̈ve
patients.1–5 Ritonavir-boosted atazanavir given at a dose of
300/100 mg once daily in combination with fixed-dose teno-
fovir and emtricitabine 300/200 mg once daily offers highly
effective antiviral activity with a good safety profile.5,6
Many HIV-infected patients experience clinically signifi-
cant alterations in gastric pH, and dyspepsia is common.7–9
Symptoms of heartburn and gastroesophageal reflux disease
are often treated with prescription or with over-the-counter
acid-suppressing agents, including antacids, proton-pump
inhibitors, and H2-receptor antagonists.
8,9 Gastric acid-sup-
pressing agents may interfere with absorption of drugs when
gastric pH is an important determinant of their solubility
and/or bioavailability. Atazanavir is a bisulfate salt and its
solubility decreases in vitro with increasing pH. The adequate
absorption of atazanavir is dependent on an acidic gastric
environment,10–13 therefore, a significant pharmacokinetic
interaction could result between acid-suppressing agents and
atazanavir.12
Previous interaction studies in healthy HIV-uninfected
subjects given atazanavir/ritonavir with or without tenofovir
disoproxil fumarate (TDF) and the H2-receptor antagonist
famotidine have shown that famotidine 40 mg twice daily,
when coadministered with atazanavir/ritonavir 300/100 mg
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once daily without TDF, decreased atazanavir area under the
plasma concentration–time curve (AUC) and minimum
plasma concentrations (Cmin) by approximately 18% and 28%,
respectively.14 Increasing the atazanavir dose to 400 mg plus
ritonavir 100 mg once daily when given with famotidine
40 mg twice daily mitigated the effect of famotidine, resulting
in similar atazanavir AUC and less decrease in Cmin (14%)
when compared with atazanavir/ritonavir 300/100 mg
without famotidine.14 In subjects administered atazanavir/
ritonavir 300/100 mg with TDF, coadministration of famoti-
dine 20 mg twice daily (with or without a temporal separation
from atazanavir) had no significant effect on atazanavir
maximum plasma concentrations (Cmax) and AUC, and de-
creased atazanavir Cmin by 18–20%.
15
Since the exposures to atazanavir are usually lower in pa-
tients with HIV infection than in healthy individuals16,17
(potentially due to reduced gastric acid secretions in HIV-
infected patients), it is suspected that the effect of an H2-
receptor antagonist on atazanavir exposure could be more
pronounced in HIV-infected patients than has been observed
in healthy subjects. This study was therefore designed to
evaluate the effect of the H2-receptor antagonist famotidine on
the pharmacokinetics of atazanavir/ritonavir in HIV-infected
patients. Moreover, since TDF, which as part of an anti-
retroviral treatment (ART) backbone is often used in con-
junction with atazanavir, has also been shown to reduce the
exposures of atazanavir, this study included an additional
group of patients who received both atazanavir/ritonavir and
TDF to fully assess the total impact of an H2-receptor antag-
onist on the exposures of atazanavir in the presence of TDF.
Materials and Methods
Study design
This study was an open-label, two-cohort, three-period,
multiple-dose, sequential, multicenter study in HIV-infected
patients receiving continuous ART containing atazanavir/
ritonavir 300/100 mg once daily and two or more nucleoside
reverse transcriptase inhibitors (NRTIs; either with or without
TDF) for at least 3 months prior to enrollment. The study was
conducted at four clinical sites (three in the United States and
one in the United Kingdom) from December 2006 to Decem-
ber 2007.
The primary objective of the study was to assess the effect
of multiple-dose famotidine twice daily on the multiple-dose
pharmacokinetics of atazanavir/ritonavir in HIV-infected
patients when famotidine and atazanavir/ritonavir were
administered simultaneously (without TDF) or temporally
separated (with TDF).
Secondary objectives were to assess the pharmacokinetics
of ritonavir coadministered with atazanavir in the presence
and absence of famotidine and to assess the safety and toler-
ability of atazanavir/ritonavir when coadministered with
famotidine in the presence of at least two NRTIs.
Subjects
This study was conducted in accordance with Good Clin-
ical Practice and the ethical principles of the Declaration of
Helsinki. The protocol was approved by the Institutional
Review Board at each study site. All subjects provided written
informed consent prior to participation in the study.
Patients were eligible for the study if they met the following
criteria: aged 18–65 years and deemed by the investigator to
have an acceptable medical history for inclusion; CD4 count
greater than 200 cells/mm3; plasma HIV RNA less than 400
copies per milliliter at least 6 weeks prior to enrollment,
within 3 weeks prior to dosing with famotidine, and at 2 days
prior to dosing with famotidine; and no history of virologic
failure on a PI or documented phenotypic PI resistance or
primary PI mutations according to International AIDS Society
recommendations (see also www.clinicaltrials.gov study
NCT00384904).
Patients who had been receiving an antiretroviral regimen
without TDF were enrolled into cohort 1 and received treat-
ments A, B, and C, while patients who had been receiving an
antiretroviral regimen including TDF were enrolled into co-
hort 2 and received treatments D, E, and F, as shown in Fig. 1.
The administration of atazanavir/ritonavir antiretroviral
regimens including TDF was temporally separated from the
administration of famotidine to avoid further reduction in
atazanavir concentrations caused by TDF.
All regimens containing atazanavir/ritonavir were ad-
ministered orally with 240 mL of water within 5 min after
completion of a light meal (total calories [kcal] approximately
336).
Safety was assessed based on medical review of adverse
event (AE) reports, vital signs, electrocardiograms, physical
examination findings, and clinical laboratory results. There
were safety laboratory profiles obtained at screening, day 2,
prior to atazanavir/ritonavir dosing on days 11 and 18, and at
study discontinuation (or completion; day 25).
Bioanalytical methods
Blood samples (2 mL) were collected with K3EDTA as an-
ticoagulant on days 10, 17, and 24 for the analysis of complete
atazanavir and ritonavir pharmacokinetic profiles. Specimens
were processed within 60 min of collection. Plasma samples
were analyzed centrally by AtlanBio, St Nazaire, France, by
liquid chromatography tandem mass spectrometry (LC-MS/
MS). The LC-MS/MS quality control deviations from nominal
concentration for atazanavir in the range of 10–10,000 ng/mL
were – 5.0%, and for ritonavir in the range of 5–5000 ng/
mL, – 1.0%.
Pharmacokinetic methods
Noncompartmental pharmacokinetic analysis was per-
formed using a validated computer program (KineticaTM
version 4.4.1; Thermo Electron Corporation, Philadelphia,
PA) to assess Cmax, time of Cmax (Tmax), Cmin, and AUC curve
in one dosing interval (AUC[TAU]).
The Cmax and Tmax were recorded from experimental ob-
servations for each treatment period. The Cmin was recorded
as the trough plasma concentration at 24 h postdose. The
AUC(TAU) was calculated by linear and log-linear trapezoidal
summation using a mixed log-linear algorithm.
Statistical analyses
All statistical analyses were carried out using SAS/STAT
Version 8.2 (SAS Institute, Inc., Cary, NC). Point estimates
and 90% confidence intervals (CIs) for the geometric mean
ratios of atazanavir and ritonavir Cmax, AUC(TAU), and Cmin,
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with and without famotidine, were constructed for each co-
hort in order to estimate the effect of different treatments and
schedules.
Specifically, analyses were made of the effect of famotidine
40 mg twice daily on the pharmacokinetics of atazanavir/
ritonavir when dosed simultaneously (treatment B versus
treatment A); famotidine 20 mg twice daily on the pharma-
cokinetics of atazanavir/ritonavir when dosed simulta-
neously (treatment C versus treatment A); famotidine 40 mg
twice daily on the pharmacokinetics of atazanavir/ritonavir
coadministered with TDF when temporally spaced from fa-
motidine (treatment E versus treatment D); and famotidine
20 mg twice daily on the pharmacokinetics of atazanavir/
ritonavir coadministered with TDF when temporally spaced
from famotidine (treatment F versus treatment D).
Estimates were generated using general linear models on
log-transformed data, with treatment as a fixed effect and
measurements within each subject as repeated measurements.
Point estimates and 90% CIs for differences on the log scale
were exponentiated to obtain estimates for ratios of geometric
means on the original scale. Treatment periods when ataza-
navir was administered without famotidine (treatment A and
treatment D) were the reference for all comparisons. No ad-
justments were made for multiplicity.
Although the sample size was not based on statistical
power considerations, 18 evaluable subjects in each cohort
were to provide at least 85% and 92% confidence that the
estimated ratios of the geometric means for atazanavir
AUC(TAU) and Cmax, respectively, with or without famotidine,
would be within 10% of the true ratios. In addition, 18 eva-
luable subjects were to provide at least 91% confidence that
the corresponding estimate for atazanavir Cmin would be
within 20% of the true ratio. To allow for dropouts, an ade-
quate number of subjects would be needed to meet the in-
clusion/exclusion criteria at screening so that 18 subjects
would complete each cohort.
Results
Patient disposition, demographics, and baseline
characteristics
A total of 40 patients were enrolled in the study (18 in
cohort 1 and 22 in cohort 2). The demographics and baseline
characteristics of patients are shown in Table 1. Within cohort
1, 17 patients completed the study while 1 treated patient was
Table 1. Patient Demographic Characteristics
Characteristic Cohort 1 (n = 18) Cohort 2 (n = 22a)
Mean age yr (range) 43 (26–63) 40 (26–54)
Gender n (%)
Male 14 (78) 21 (95)
Female 4 (22) 1 (5)
Race n (%)
Caucasian 9 (50) 13 (59)
Black 6 (33) 4 (18)
Asian 0 3 (14)
Other 3 (17) 2 (9)
Body mass index
kg/m2
Mean (range) 25.6 (19.3–34.3) 25.0 (20.4–29.6)
CD4 count in cells/lL
Mean (SD) 663 (258) 577 (175)
(range) (261–1000) (317–907)
aIncludes the four subjects who were incorrectly dosed with
famotidine.
Cohort 1: atazanavir/ritonavir 300/100 mg once daily with 2 or
more NRTIs (without TDF) dosed simultaneously with famotidine
twice daily (treatments A, B, and C).
Cohort 2: atazanavir/ritonavir/TDF 300/100/300 mg once daily
with 1 or more additional NRTI(s) dosed temporally separated from
famotidine BID (treatments D, E, and F).
NRTI(s), nucleoside reverse transcriptase inhibitor(s); TDF, teno-
fovir disoproxil fumurate; SD, standard deviation.
FIG. 1. Study design. In
cohort 1 the morning dose of
FAM was administered
simultaneously with ATV/
RTV and subjects received
the following treatments
orally: A: Morning dosing of
ATV/RTV 300/100 mg QD
for 10 days (days 1–10). B:
Morning dosing of ATV/
RTV 300/100 mg QD + FAM
40 mg twice daily for 7 days
(days 11–17). C: Morning
dosing of ATV/RTV 300/
100 mg QD + FAM 20 mg
twice daily for 7 days (days
18–24). In cohort 2 ATV/
RTV/TDF was temporarily
separated from FAM by ad-
ministering 2 h before morn-
ing FAM and 10 h after afternoon FAM, and subjects received the following treatments orally: D: Morning dosing of ATV/
RTV/TDF 300/100/300 mg QD for 10 days (days 1–10); E: Morning dosing of ATV/RTV/TDF 300/100/300 mg QD + FAM
40 mg twice daily for 7 days (days 11–17); and F: Morning dosing of ATV/RTV/TDF 300/100/300 mg QD + FAM 20 mg
twice daily for 7 days (days 18–24). + Treatments A, B, and C included ‡ 2 NRTIs other than TDF. – Treatments D, E, and F
included ‡ 1 NRTIs other than TDF. ATV, atazanavir; FAM, famotidine; QD, once daily; RTV, ritonavir.
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removed due to poor compliance after completing treatment
A. This patient was excluded from the pharmacokinetic
analysis but included in the safety analysis. Within cohort 2,
19 of the 22 patients completed the study. Four patients were
incorrectly dosed with famotidine. Of these 4 patients, 1
completed the study and 3 were discontinued prior to com-
pleting the study. The patient who completed the study also
incorrectly received atazanavir/ritonavir plus TDF without
another NRTI. In this patient, follow-up through 3 weeks after
study completion showed that viral loads were undetectable
(HIV RNA less than 400 copies per milliliter). The 4 patients
incorrectly dosed with famotidine were excluded from the
pharmacokinetic analysis but included in the safety analysis.
Pharmacokinetics
Atazanavir exposure in the absence of TDF The phar-
macokinetic and statistical analyses of atazanavir expo-
sure per treatment group are summarized in Table 2.
Plasma concentration-time profiles for atazanavir per treat-
ment group are shown in Fig. 2. Simultaneous or temporally
separated administration of famotidine 40 or 20 mg twice
daily with atazanavir/ritonavir 300/100 mg once daily de-
creased atazanavir exposures when compared with atazanavir/
ritonavir alone.
Using the geometric mean ratios (Table 2), atazanavir Cmax,
AUC(TAU), and Cmin were 23%, 23%, and 20% lower, respec-
tively, after patients received famotidine 40 mg coadminis-
tered with atazanavir/ritonavir (treatment B) compared with
atazanavir/ritonavir alone (treatment A). Coadministration
of famotidine 20 mg twice daily (treatment C) had less impact
on atazanavir exposures. Using the geometric mean ratios,
atazanavir Cmax, AUC(TAU), and Cmin were 20%, 13%, and 1%
lower, respectively, in treatment C than in treatment A. Figure
3 shows the comparison of atazanavir Cmin for each individ-
ual patient in cohort 1. Despite the individual variation, the
trend of reduction in atazanavir exposures with famotidine
administration was consistent in most patients.
Atazanavir exposure in the presence of TDF. Using the
geometric mean ratios (Table 2), atazanavir Cmax, AUC(TAU),
and Cmin were 23%, 24%, and 25% lower respectively, after
receiving famotidine 40 mg temporally separated from ata-
zanavir/ritonavir/TDF (treatment E) compared with ataza-
navir/ritonavir/TDF alone (treatment D). Administration of
famotidine 20 mg twice daily with atazanavir/ritonavir/TDF
with temporal separation (treatment F) had slightly less
impact on atazanavir exposures. Using the geometric mean
Table 2. Pharmacokinetic Analyses for Atazanavir Exposurea
Treatment Cmax (ng/mL) AUC(TAU) (ng.h/mL) Cmin (ng/mL)
Cohort 1
A: ATV/RTV 4,572 (32) 39,831 (33) 588 (61)
B: ATV/RTV + famotidine 40 mg 3,592 (33) 31,787 (34) 492 (49)
C: ATV/RTV + famotidine 20 mg 3,687 (33) 35,322 (30) 610 (51)
Treatment B/A: Rb (90% CI) 0.77 (0.67–0.88) 0.77 (0.68–0.86) 0.80 (0.69–0.92)
Treatment C/A: Rb (90% CI) 0.80 (0.68–0.93) 0.87 (0.75–1.01) 0.99 (0.84–1.18)
Cohort 2
D: ATV/RTV/TDF 3987 (35) 36,015 (41) 542 (62)
E: ATV/RTV/TDF + famotidine 40 mg 3057 (54) 27,178 (45) 409 (64)
F: ATV/RTV/TDF + famotidine 20 mg 3130 (56) 28,586 (61) 441 (91)
Treatment E/D: Rb (90% CI) 0.77 (0.64–0.92) 0.76 (0.64–0.89) 0.75 (0.53–1.07)
Treatment F/D: Rb (90% CI) 0.79 (0.64–0.96) 0.79 (0.66–0.96) 0.81 (0.63–1.05)
aThe values are reported as geometric means (coefficient of variation %) unless otherwise indicated
bR is the ratio of adjusted geometric means (90% CI) for the treatment periods when atazanavir was administered with famotidine
(treatments B, C, E, and F) to those when atazanavir was administered without famotidine (treatments A and D).
ATV, atazanavir; RTV, ritonavir; CI, confidence interval; TDF, tenofovir disoproxil fumarate.
FIG. 2. Mean (standard deviation, SD) plasma concentra-
tion–time profiles for atazanavir by treatment.
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ratios atazanavir Cmax, AUC(TAU), and Cmin were 21%, 21%,
and 19% lower, respectively (for treatment F), than those for
treatment D. Figure 3 shows the comparison of atazanavir
Cmin for each individual patient in cohort 2.
Ritonavir exposure. The ritonavir exposures were com-
parable across all treatments, such that simultaneous or
temporally separated administration of famotidine 40 or
20 mg twice daily with atazanavir/ritonavir with or without
TDF once daily had minimal effects on ritonavir exposures
(data not shown).
Safety
There were no deaths, serious AEs, or discontinuations due
to AEs in the study. Elevations in total bilirubin occurred in 7
(17.5%) patients (4 in cohort 1 and 3 in cohort 2). One patient
experienced jaundice following administration of famotidine
20 mg temporally separated from atazanavir/ritonavir/TDF
(treatment F). Headache was the most frequently observed
treatment-related AE reported in 12 subjects (30%), followed
by diarrhea in 6 subjects (15%). The AEs of headache were
mild in intensity and those of diarrhea were mild or moderate
in intensity. The remainder of reported AEs occurred only one
or two times per treatment. There were no significant elec-
trocardiographic or vital sign changes in any patients.
All patients who completed the study remained virologi-
cally suppressed at a level of less than 400 copies per milliliter
at study completion.
Discussion
This study assessed the effect of coadministration of a
commonly used H2-receptor antagonist, famotidine, on ata-
zanavir/ritonavir exposure in HIV-infected patients. While
many antiretroviral regimen pharmacokinetic studies have
been performed in healthy HIV-uninfected subjects, it is
known that atazanavir exposures in HIV patients can be
30–50% lower than those in healthy HIV-uninfected sub-
jects.16 Through direct study of atazanavir/ritonavir drug
interactions in HIV-infected patients, it is possible to investi-
gate drug interactions in clinically relevant populations and
test the relevance of pharmacokinetic results obtained from
studies conducted in HIV-uninfected cohorts.
In this study of HIV-infected patients, coadministration of
famotidine 40 mg twice daily and atazanavir/ritonavir 300/
100 mg once daily reduced the exposure of atazanavir by
20–23%. The magnitude of this reduction is comparable
to that noted in healthy HIV-uninfected subjects, in whom
14–28% decreases in atazanavir exposure were observed.14
In addition, this study in HIV-infected patients found that a
lower dose of famotidine (20 mg twice daily) had less impact
on atazanavir exposures, particularly Cmin (approximately 1%
decrease).
In the presence of TDF, the magnitude of the famotidine
(40 mg twice daily)-induced reduction in atazanavir exposure
seen in the present study in HIV-infected subjects (23–25% ) is
generally comparable to the 21–28% reductions noted in
healthy subjects.15 The impact of famotidine 20 mg twice daily
FIG. 3. Individual atazanavir pharmacokinetic exposures (Cmin) by treatment.
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was somewhat greater on Cmax and AUC in HIV-infected
patients than in healthy subjects (i.e., decreases of 20% versus
no effect), whereas a similar effect on Cmin was observed (19%
versus 18% in healthy subjects).15 The mechanism and clinical
relevance for the observed difference is uncertain. However,
the magnitude of the reduction in atazanavir exposures by
coadministration of TDF (approximately 10%, treatment D
versus A) was less than the previously observed 25% reduc-
tion in healthy subjects.18 This difference may be explained by
the different study design in the two studies: this study was
conducted in parallel groups whereas the previous study was
conducted in a crossover fashion. Nonetheless, the effects of
TDF on atazanavir exposure do not appear to impact the
antiretroviral efficacy of the combination regimen as dem-
onstrated in the CASTLE study.5
Despite the reduction in atazanavir Cmin with famotidine
and/or TDF administration, an important finding of the
present study is that all individual Cmin values for atazanavir
on days 10, 17, and 24 (data not shown) remained at least
fivefold above the population mean protein-binding adjusted
concentration required to obtain 90% of the maximum effect
(EC90) against wild-type HIV (EC90 = 14 ng/mL after correct-
ing for human serum binding effects).19 The lowest atazanavir
Cmin among all treated patients in the current study was
70.5 ng/mL. These findings are in keeping with the observa-
tion in this study that concomitant use of famotidine and/or
TDF with atazanavir was associated with continued virologic
suppression. These results support the recommendation that
in treatment-naive patients, further dose adjustment for ata-
zanavir is not necessary. However, for treatment-experienced
patients, a higher ratio of atazanavir Cmin to EC90 may be
needed to achieve optimal antiviral efficacy. It has been
shown previously in healthy subjects that an increase in ata-
zanavir dose to 400 mg can mitigate the reduction in ataza-
navir exposures caused by TDF and famotidine.14,18
Increasing the atazanavir dose to 400 mg would alleviate the
potential double impact on atazanavir exposures by both of
these coadministered drugs and ensure that atazanavir Cmin
is maintained within the therapeutic range in treatment-
experienced patients.
A limitation of the current study is the low percentage of
women (12.5%) enrolled, which is not untypical for PK studies
conducted in HIV patients.
In summary, the findings of the current study are consistent
with previous data from healthy HIV-uninfected subjects, and
support the current dosing recommendations when atazana-
vir and H2-receptor antagonist coadministration is indicated
in antiretroviral-naive patients that an H2-receptor antagonist
dose equivalent to famotidine 20–40 mg twice daily can be
used with atazanavir/ritonavir 300/100 mg once daily. For
treatment-experienced patients who are taking the atazana-
vir/ritonavir regimen, an H2-receptor antagonist may be gi-
ven at a dose not to exceed the equivalent of famotidine 20 mg
twice daily. For treatment-experienced patients who are also
taking TDF, the atazanavir dose should be adjusted to 400 mg
with ritonavir 100 mg. For all patients taking an H2-receptor
antagonist, atazanavir/ritonavir should be given simulta-
neously with or at least 10 h after the dose of the H2-receptor
antagonist.2,20 These approaches to antiretroviral dosing and
temporal spacing of coadministered H2-receptor antagonists
ensure that atazanavir exposures are adequate across all
groups of HIV-infected patients.
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